- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 690 Lee Road Wayne PA United States of America 19087
- IPO Date
- Apr 28, 2000
- Business
- The Hartford Healthcare Fund Class A (HGHAX) is an open-end mutual fund that seeks long-term capital appreciation through active investment primarily in equity securities of health care companies worldwide. The fund invests across major health care subsectors, including pharmaceuticals, biotechnology, medical devices, health care services, managed care, medical delivery systems, health information services, and emerging health-related areas; it maintains representation in biopharma large-cap (approximately 40%), medical technology (26%), health care services (18%), biopharma mid-cap (13%), and biopharma small-cap (3%), with top holdings such as Eli Lilly & Co. (13%), UnitedHealth Group Inc., Boston Scientific Corp., Johnson & Johnson, and Merck & Co., Inc. Class A shares feature a 5.50% front-end load, a net expense ratio of 1.29%, and a minimum initial investment of $2,000; the fund is sub-advised by Wellington Management Company LLP, with portfolio manager Rebecca Sykes, CFA, since September 2020.
Launched on May 1, 2000, the fund is managed by Hartford Funds, a subsidiary of The Hartford Financial Services Group, Inc., headquartered in Wayne, Pennsylvania. It primarily targets U.S. investors through distribution channels including broker-dealers and financial advisors, with assets under management of approximately $737 million and a portfolio turnover rate of around 43%; geographic exposure is predominantly U.S.-focused (about 90%), with smaller allocations to Europe, the United Kingdom, Eurozone, Japan, and other regions.
In recent developments, Hartford Funds launched its first options overlay strategy, the Hartford Equity Premium Income ETF (HEMI), on December 16, 2025, sub-advised by Wellington Management to generate income via U.S. equities and S&P 500 call options, reflecting broader innovation in outcome-oriented products. The fund continues to benefit from Wellington's sub-advisory partnership, emphasizing independent research and collaboration; no major acquisitions, funding rounds, or reorganizations specific to HGHAX were reported in the last 1-2 years, though the firm maintains strategic alliances with partners like Schoder and MIT AgeLab for enhanced investor solutions.